<DOC>
	<DOCNO>NCT00426556</DOCNO>
	<brief_summary>Phase I : look different dose level regimens everolimus combined weekly trastuzumab paclitaxel therapy patient HER-2 overexpressing metastatic breast cancer . Phase II : ass efficacy safety 10mg daily dose everolimus combine weekly trastuzumab paclitaxel therapy patient HER-2 overexpressing metastatic breast cancer .</brief_summary>
	<brief_title>Efficacy Safety Everolimus Combination Therapy , Patients With HER2-overexpressing Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female male patient ≥ 18 year old WHO performance status ≤ 1 HER2 overexpressing metastatic breast cancer cell confirm histology Progressive disease prior trastuzumab alone/or combination anticancer agent , relapse time completion therapy ( phase l ) Patient resistance trastuzumab taxanes ( Phase ) Measurable disease accord RECIST ( Phase ) Patients neurologically stable adequate bone marrow , liver renal function Patients receive endocrine therapy breast cancer ≤ 2 week prior study treatment start Patients currently receive chemotherapy , immunotherapy radiotherapy receive ≤ 4 week prior study treatment start patient receive lapatinib ≤ 2 week prior study treatment start Patients previously receive mTOR inhibitor Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Cancer breast</keyword>
	<keyword>Human mammary carcinoma</keyword>
	<keyword>HER-2</keyword>
	<keyword>Metastatic</keyword>
	<keyword>everolimus</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>paclitaxel</keyword>
</DOC>